Isaac Bright

RubrYc Therapeutics, Inc. develops antibody therapy applications. Its products include RubrYc Discovery Engine, through which people can decode protein interactions through the integration of data and biological science. The company was founded in 2017 and is headquartered in San Carlos, CA.

RubrYc Therapeutics, Inc. develops antibody therapy applications. Its products include RubrYc Discovery Engine, through which people can decode protein interactions through the integration of data and biological science. The company was founded in 2017 and is headquartered in San Carlos, CA.

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

QuantaLife, Inc. operates as a biotechnology company. It develops and manufactures products based on nucleic acid testing concept for the life science research, clinical molecular diagnostics, personalized medical care and industrial markets. The company was founded by Kevin Dean Ness, Benjamin Hindson, Christopher T. Blisard and William Wayne Colston Jr. in 2008 and is headquartered in Boulder, CO.

Medtronic Ltd. engages in the development and manufacturing of medical equipment for people with chronic disease. It offers products and therapies for cardiac rhythm disease management, neuromodulation, spinal and biologics, diabetes, cardiovascular, and ear, nose, and throat diseases. The company was founded by Earl E. Bakken and Palmer Hermundslie in 1949 and is headquartered in Watford, the United Kingdom.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.